nodes	percent_of_prediction	percent_of_DWPC	metapath
Nelarabine—DGUOK—Nucleotide metabolism—NME2—ovarian cancer	0.0206	0.098	CbGpPWpGaD
Nelarabine—DGUOK—myometrium—ovarian cancer	0.0154	0.0625	CbGeAlD
Nelarabine—POLA1—Nucleotide Metabolism—NME2—ovarian cancer	0.0143	0.068	CbGpPWpGaD
Nelarabine—DGUOK—uterine cervix—ovarian cancer	0.012	0.0487	CbGeAlD
Nelarabine—DGUOK—decidua—ovarian cancer	0.0114	0.0464	CbGeAlD
Nelarabine—DGUOK—endometrium—ovarian cancer	0.0108	0.044	CbGeAlD
Nelarabine—DGUOK—uterus—ovarian cancer	0.00996	0.0405	CbGeAlD
Nelarabine—POLA1—myometrium—ovarian cancer	0.00948	0.0386	CbGeAlD
Nelarabine—DGUOK—female reproductive system—ovarian cancer	0.00896	0.0365	CbGeAlD
Nelarabine—ADA—myometrium—ovarian cancer	0.00879	0.0358	CbGeAlD
Nelarabine—DGUOK—bone marrow—ovarian cancer	0.00846	0.0344	CbGeAlD
Nelarabine—DGUOK—female gonad—ovarian cancer	0.00815	0.0332	CbGeAlD
Nelarabine—DGUOK—vagina—ovarian cancer	0.0081	0.033	CbGeAlD
Nelarabine—POLA1—uterine cervix—ovarian cancer	0.00737	0.03	CbGeAlD
Nelarabine—DGUOK—testis—ovarian cancer	0.00723	0.0294	CbGeAlD
Nelarabine—POLA1—decidua—ovarian cancer	0.00703	0.0286	CbGeAlD
Nelarabine—ADA—Nucleotide metabolism—NME2—ovarian cancer	0.00683	0.0325	CbGpPWpGaD
Nelarabine—POLA1—Vinblastine—Vinorelbine—ovarian cancer	0.0068	0.675	CbGdCrCtD
Nelarabine—POLA1—endometrium—ovarian cancer	0.00667	0.0271	CbGeAlD
Nelarabine—ADA—decidua—ovarian cancer	0.00652	0.0265	CbGeAlD
Nelarabine—DCK—Nucleotide metabolism—NME2—ovarian cancer	0.00631	0.03	CbGpPWpGaD
Nelarabine—DCK—myometrium—ovarian cancer	0.00584	0.0238	CbGeAlD
Nelarabine—Cladribine—NR5A1—ovarian cancer	0.00566	0.704	CrCbGaD
Nelarabine—DCK—embryo—ovarian cancer	0.00562	0.0229	CbGeAlD
Nelarabine—DGUOK—lymph node—ovarian cancer	0.00524	0.0213	CbGeAlD
Nelarabine—POLA1—bone marrow—ovarian cancer	0.00522	0.0212	CbGeAlD
Nelarabine—POLA1—Inhibition of replication initiation of damaged DNA by RB1/E2F1—PPP2R1A—ovarian cancer	0.00513	0.0244	CbGpPWpGaD
Nelarabine—ADA—female reproductive system—ovarian cancer	0.00512	0.0209	CbGeAlD
Nelarabine—POLA1—female gonad—ovarian cancer	0.00503	0.0205	CbGeAlD
Nelarabine—POLA1—vagina—ovarian cancer	0.005	0.0203	CbGeAlD
Nelarabine—ADA—bone marrow—ovarian cancer	0.00484	0.0197	CbGeAlD
Nelarabine—POLA1—Chromosome Maintenance—RSF1—ovarian cancer	0.00472	0.0225	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—TP63—ovarian cancer	0.00471	0.0224	CbGpPWpGaD
Nelarabine—DGUOK—Nucleotide metabolism—TYMS—ovarian cancer	0.00467	0.0222	CbGpPWpGaD
Nelarabine—ADA—vagina—ovarian cancer	0.00463	0.0189	CbGeAlD
Nelarabine—DCK—uterine cervix—ovarian cancer	0.00455	0.0185	CbGeAlD
Nelarabine—POLA1—testis—ovarian cancer	0.00446	0.0181	CbGeAlD
Nelarabine—DCK—decidua—ovarian cancer	0.00433	0.0176	CbGeAlD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—TP63—ovarian cancer	0.00421	0.02	CbGpPWpGaD
Nelarabine—ADA—testis—ovarian cancer	0.00414	0.0168	CbGeAlD
Nelarabine—DCK—endometrium—ovarian cancer	0.00411	0.0167	CbGeAlD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—BARD1—ovarian cancer	0.00407	0.0194	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—YAP1—ovarian cancer	0.00387	0.0184	CbGpPWpGaD
Nelarabine—DCK—gonad—ovarian cancer	0.00381	0.0155	CbGeAlD
Nelarabine—DCK—uterus—ovarian cancer	0.00379	0.0154	CbGeAlD
Nelarabine—DCK—Pyrimidine metabolism—TYMS—ovarian cancer	0.00367	0.0175	CbGpPWpGaD
Nelarabine—POLA1—G1/S-Specific Transcription—CCNE1—ovarian cancer	0.00361	0.0172	CbGpPWpGaD
Nelarabine—POLA1—G1/S-Specific Transcription—TYMS—ovarian cancer	0.00354	0.0169	CbGpPWpGaD
Nelarabine—DCK—female reproductive system—ovarian cancer	0.00341	0.0139	CbGeAlD
Nelarabine—POLA1—lymph node—ovarian cancer	0.00323	0.0132	CbGeAlD
Nelarabine—DCK—bone marrow—ovarian cancer	0.00322	0.0131	CbGeAlD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—FASN—ovarian cancer	0.00316	0.015	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—TP63—ovarian cancer	0.00311	0.0148	CbGpPWpGaD
Nelarabine—DCK—female gonad—ovarian cancer	0.0031	0.0126	CbGeAlD
Nelarabine—DCK—vagina—ovarian cancer	0.00308	0.0125	CbGeAlD
Nelarabine—ADA—lymph node—ovarian cancer	0.003	0.0122	CbGeAlD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—BARD1—ovarian cancer	0.00298	0.0142	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—GADD45A—ovarian cancer	0.00282	0.0134	CbGpPWpGaD
Nelarabine—DCK—testis—ovarian cancer	0.00275	0.0112	CbGeAlD
Nelarabine—ADA—p73 transcription factor network—YAP1—ovarian cancer	0.00256	0.0122	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—RBL2—ovarian cancer	0.00252	0.012	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—ovarian cancer	0.00244	0.0116	CbGpPWpGaD
Nelarabine—POLA1—E2F mediated regulation of DNA replication—PPP2R1A—ovarian cancer	0.00229	0.0109	CbGpPWpGaD
Nelarabine—POLA1—E2F mediated regulation of DNA replication—CCNE1—ovarian cancer	0.00212	0.0101	CbGpPWpGaD
Nelarabine—POLA1—E2F mediated regulation of DNA replication—TYMS—ovarian cancer	0.00208	0.00992	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—FASN—ovarian cancer	0.00208	0.00992	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—TOP1—ovarian cancer	0.00207	0.00983	CbGpPWpGaD
Nelarabine—Adenosine triphosphate—AKT1—ovarian cancer	0.00203	0.252	CrCbGaD
Nelarabine—POLA1—Extension of Telomeres—TERT—ovarian cancer	0.00201	0.00958	CbGpPWpGaD
Nelarabine—DCK—lymph node—ovarian cancer	0.00199	0.00811	CbGeAlD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—SKP2—ovarian cancer	0.00199	0.00947	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—NME2—ovarian cancer	0.00187	0.0089	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—PPP1CC—ovarian cancer	0.00181	0.00859	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.00178	0.00848	CbGpPWpGaD
Nelarabine—DCK—Doxorubicin—Epirubicin—ovarian cancer	0.0017	0.169	CbGdCrCtD
Nelarabine—ADA—p73 transcription factor network—BRCA2—ovarian cancer	0.00161	0.00768	CbGpPWpGaD
Nelarabine—DCK—Epirubicin—Doxorubicin—ovarian cancer	0.00157	0.156	CbGdCrCtD
Nelarabine—ADA—Circadian rythm related genes—HNF1B—ovarian cancer	0.00157	0.00745	CbGpPWpGaD
Nelarabine—ADA—Nucleotide metabolism—TYMS—ovarian cancer	0.00155	0.00738	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—RBL2—ovarian cancer	0.00154	0.00733	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—SKP2—ovarian cancer	0.00146	0.00693	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.00145	0.00692	CbGpPWpGaD
Nelarabine—DCK—Nucleotide metabolism—TYMS—ovarian cancer	0.00143	0.00681	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CCNE1—ovarian cancer	0.00134	0.00635	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—TYMS—ovarian cancer	0.00131	0.00624	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—BRCA1—ovarian cancer	0.00128	0.00611	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—SKP2—ovarian cancer	0.00122	0.00578	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—CYTB—ovarian cancer	0.00121	0.00574	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—RSF1—ovarian cancer	0.0012	0.0057	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—CCNE1—ovarian cancer	0.00112	0.00535	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—TYMS—ovarian cancer	0.0011	0.00526	CbGpPWpGaD
Nelarabine—POLA1—S Phase—SKP2—ovarian cancer	0.0011	0.00525	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—BRIP1—ovarian cancer	0.00105	0.00501	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PPP1CC—ovarian cancer	0.00105	0.00501	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—SKP2—ovarian cancer	0.00102	0.00487	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CCNE1—ovarian cancer	0.000977	0.00465	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—TYMS—ovarian cancer	0.00096	0.00457	CbGpPWpGaD
Nelarabine—POLA1—Telomere Maintenance—TERT—ovarian cancer	0.000912	0.00434	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—PPP2R1A—ovarian cancer	0.000879	0.00418	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—PPP1CC—ovarian cancer	0.000822	0.00391	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—CCNE1—ovarian cancer	0.000816	0.00388	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—TYMS—ovarian cancer	0.000801	0.00381	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CCND2—ovarian cancer	0.000785	0.00374	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—CDKN1B—ovarian cancer	0.000771	0.00367	CbGpPWpGaD
Nelarabine—POLA1—Chromosome Maintenance—TERT—ovarian cancer	0.00076	0.00362	CbGpPWpGaD
Nelarabine—POLA1—S Phase—CCNE1—ovarian cancer	0.000741	0.00353	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—PPP2R1A—ovarian cancer	0.000741	0.00352	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—CCND1—ovarian cancer	0.000736	0.0035	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—TYMS—ovarian cancer	0.000727	0.00346	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—YAP1—ovarian cancer	0.000707	0.00336	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.000695	0.00331	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CDKN1B—ovarian cancer	0.000692	0.00329	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CCNE1—ovarian cancer	0.000688	0.00327	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—TYMS—ovarian cancer	0.000675	0.00321	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—ovarian cancer	0.00066	0.00314	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000635	0.00302	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—NRAS—ovarian cancer	0.000634	0.00302	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—RAD51C—ovarian cancer	0.000629	0.00299	CbGpPWpGaD
Nelarabine—ADA—Metabolism—NME2—ovarian cancer	0.000621	0.00296	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—MYC—ovarian cancer	0.00062	0.00295	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—PPP1CC—ovarian cancer	0.000615	0.00293	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000595	0.00283	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—MYC—ovarian cancer	0.00059	0.00281	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—CDKN1B—ovarian cancer	0.000583	0.00277	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—FASN—ovarian cancer	0.000576	0.00274	CbGpPWpGaD
Nelarabine—DCK—Metabolism—NME2—ovarian cancer	0.000573	0.00273	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—SLC5A5—ovarian cancer	0.000567	0.0027	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—RBL2—ovarian cancer	0.000565	0.00269	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—PPP1CC—ovarian cancer	0.00055	0.00262	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—SLC2A1—ovarian cancer	0.000547	0.0026	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—KRAS—ovarian cancer	0.000545	0.0026	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.000538	0.00256	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	0.00053	0.00252	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—CYP1B1—ovarian cancer	0.000525	0.0025	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.000521	0.00248	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.000521	0.00248	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.000512	0.00243	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CDKN1B—ovarian cancer	0.000507	0.00241	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—RBL2—ovarian cancer	0.000505	0.0024	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—ovarian cancer	0.000483	0.0023	CbGpPWpGaD
Nelarabine—POLA1—Synthesis of DNA—CDKN1B—ovarian cancer	0.000468	0.00223	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PPP2R1A—ovarian cancer	0.000465	0.00221	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—HRAS—ovarian cancer	0.000464	0.00221	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—MYC—ovarian cancer	0.000446	0.00212	CbGpPWpGaD
Nelarabine—Feeling abnormal—Vinorelbine—ovarian cancer	0.000444	0.000845	CcSEcCtD
Nelarabine—Asthenia—Melphalan—ovarian cancer	0.000443	0.000842	CcSEcCtD
Nelarabine—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000441	0.000838	CcSEcCtD
Nelarabine—POLA1—DNA Replication—CDKN1B—ovarian cancer	0.000439	0.00209	CbGpPWpGaD
Nelarabine—Dysgeusia—Paclitaxel—ovarian cancer	0.000435	0.000827	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	0.000435	0.00207	CbGpPWpGaD
Nelarabine—Hypoglycaemia—Epirubicin—ovarian cancer	0.000432	0.000822	CcSEcCtD
Nelarabine—DGUOK—Metabolism—ABCB1—ovarian cancer	0.000432	0.00206	CbGpPWpGaD
Nelarabine—Diarrhoea—Topotecan—ovarian cancer	0.000431	0.00082	CcSEcCtD
Nelarabine—Hypoaesthesia—Docetaxel—ovarian cancer	0.000431	0.000819	CcSEcCtD
Nelarabine—Lethargy—Epirubicin—ovarian cancer	0.000431	0.000819	CcSEcCtD
Nelarabine—Back pain—Paclitaxel—ovarian cancer	0.00043	0.000817	CcSEcCtD
Nelarabine—Urinary tract disorder—Docetaxel—ovarian cancer	0.000427	0.000813	CcSEcCtD
Nelarabine—Abdominal pain—Vinorelbine—ovarian cancer	0.000426	0.000811	CcSEcCtD
Nelarabine—Body temperature increased—Vinorelbine—ovarian cancer	0.000426	0.000811	CcSEcCtD
Nelarabine—Oedema peripheral—Docetaxel—ovarian cancer	0.000426	0.000811	CcSEcCtD
Nelarabine—Connective tissue disorder—Docetaxel—ovarian cancer	0.000425	0.000809	CcSEcCtD
Nelarabine—DGUOK—Metabolism—TYMS—ovarian cancer	0.000424	0.00202	CbGpPWpGaD
Nelarabine—Urethral disorder—Docetaxel—ovarian cancer	0.000424	0.000807	CcSEcCtD
Nelarabine—POLA1—G1/S Transition—CDKN1B—ovarian cancer	0.000423	0.00201	CbGpPWpGaD
Nelarabine—Diarrhoea—Melphalan—ovarian cancer	0.000422	0.000803	CcSEcCtD
Nelarabine—Osteoarthritis—Epirubicin—ovarian cancer	0.000422	0.000802	CcSEcCtD
Nelarabine—Pain in extremity—Epirubicin—ovarian cancer	0.000422	0.000802	CcSEcCtD
Nelarabine—Nausea—Chlorambucil—ovarian cancer	0.000421	0.0008	CcSEcCtD
Nelarabine—Vision blurred—Paclitaxel—ovarian cancer	0.000419	0.000796	CcSEcCtD
Nelarabine—Dizziness—Topotecan—ovarian cancer	0.000417	0.000793	CcSEcCtD
Nelarabine—Tremor—Paclitaxel—ovarian cancer	0.000416	0.000792	CcSEcCtD
Nelarabine—Anaemia—Paclitaxel—ovarian cancer	0.000411	0.000781	CcSEcCtD
Nelarabine—Eye disorder—Docetaxel—ovarian cancer	0.000404	0.000769	CcSEcCtD
Nelarabine—Cardiac disorder—Docetaxel—ovarian cancer	0.000402	0.000764	CcSEcCtD
Nelarabine—Vomiting—Topotecan—ovarian cancer	0.000401	0.000762	CcSEcCtD
Nelarabine—Hypoglycaemia—Doxorubicin—ovarian cancer	0.0004	0.000761	CcSEcCtD
Nelarabine—ADA—Metabolism—CYTB—ovarian cancer	0.0004	0.0019	CbGpPWpGaD
Nelarabine—Lethargy—Doxorubicin—ovarian cancer	0.000398	0.000757	CcSEcCtD
Nelarabine—Leukopenia—Paclitaxel—ovarian cancer	0.000398	0.000756	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.000397	0.00189	CbGpPWpGaD
Nelarabine—Ataxia—Epirubicin—ovarian cancer	0.000397	0.000754	CcSEcCtD
Nelarabine—Blood creatinine increased—Epirubicin—ovarian cancer	0.000395	0.000752	CcSEcCtD
Nelarabine—Headache—Topotecan—ovarian cancer	0.000395	0.000751	CcSEcCtD
Nelarabine—Angiopathy—Docetaxel—ovarian cancer	0.000393	0.000746	CcSEcCtD
Nelarabine—Vomiting—Melphalan—ovarian cancer	0.000393	0.000746	CcSEcCtD
Nelarabine—Dehydration—Epirubicin—ovarian cancer	0.000392	0.000746	CcSEcCtD
Nelarabine—Loss of consciousness—Paclitaxel—ovarian cancer	0.000391	0.000743	CcSEcCtD
Nelarabine—Osteoarthritis—Doxorubicin—ovarian cancer	0.00039	0.000742	CcSEcCtD
Nelarabine—Pain in extremity—Doxorubicin—ovarian cancer	0.00039	0.000742	CcSEcCtD
Nelarabine—Mediastinal disorder—Docetaxel—ovarian cancer	0.00039	0.000742	CcSEcCtD
Nelarabine—Chills—Docetaxel—ovarian cancer	0.000388	0.000738	CcSEcCtD
Nelarabine—Cough—Paclitaxel—ovarian cancer	0.000388	0.000737	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	0.000388	0.00184	CbGpPWpGaD
Nelarabine—Asthenia—Vinorelbine—ovarian cancer	0.000387	0.000736	CcSEcCtD
Nelarabine—Convulsion—Paclitaxel—ovarian cancer	0.000385	0.000732	CcSEcCtD
Nelarabine—Hypokalaemia—Epirubicin—ovarian cancer	0.000384	0.00073	CcSEcCtD
Nelarabine—POLA1—S Phase—CDKN1B—ovarian cancer	0.000384	0.00183	CbGpPWpGaD
Nelarabine—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.00038	0.000722	CcSEcCtD
Nelarabine—Mental disorder—Docetaxel—ovarian cancer	0.000379	0.000721	CcSEcCtD
Nelarabine—Arthralgia—Paclitaxel—ovarian cancer	0.000378	0.000719	CcSEcCtD
Nelarabine—Myalgia—Paclitaxel—ovarian cancer	0.000378	0.000719	CcSEcCtD
Nelarabine—Chest pain—Paclitaxel—ovarian cancer	0.000378	0.000719	CcSEcCtD
Nelarabine—Malnutrition—Docetaxel—ovarian cancer	0.000377	0.000716	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—SKP2—ovarian cancer	0.000376	0.00179	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000376	0.00179	CbGpPWpGaD
Nelarabine—Nausea—Topotecan—ovarian cancer	0.000375	0.000712	CcSEcCtD
Nelarabine—Muscular weakness—Epirubicin—ovarian cancer	0.000372	0.000708	CcSEcCtD
Nelarabine—DCK—Metabolism—CYTB—ovarian cancer	0.000369	0.00176	CbGpPWpGaD
Nelarabine—Diarrhoea—Vinorelbine—ovarian cancer	0.000369	0.000702	CcSEcCtD
Nelarabine—Dysgeusia—Docetaxel—ovarian cancer	0.000369	0.000701	CcSEcCtD
Nelarabine—Abdominal distension—Epirubicin—ovarian cancer	0.000367	0.000698	CcSEcCtD
Nelarabine—Ataxia—Doxorubicin—ovarian cancer	0.000367	0.000698	CcSEcCtD
Nelarabine—Nausea—Melphalan—ovarian cancer	0.000367	0.000697	CcSEcCtD
Nelarabine—POLA1—S Phase—CCND1—ovarian cancer	0.000366	0.00174	CbGpPWpGaD
Nelarabine—Confusional state—Paclitaxel—ovarian cancer	0.000366	0.000695	CcSEcCtD
Nelarabine—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000366	0.000695	CcSEcCtD
Nelarabine—Back pain—Docetaxel—ovarian cancer	0.000364	0.000693	CcSEcCtD
Nelarabine—Dehydration—Doxorubicin—ovarian cancer	0.000363	0.00069	CcSEcCtD
Nelarabine—POLA1—Mitotic M-M/G1 phases—PPP2R1A—ovarian cancer	0.000363	0.00173	CbGpPWpGaD
Nelarabine—Oedema—Paclitaxel—ovarian cancer	0.000363	0.00069	CcSEcCtD
Nelarabine—Infection—Paclitaxel—ovarian cancer	0.00036	0.000685	CcSEcCtD
Nelarabine—Dizziness—Vinorelbine—ovarian cancer	0.000357	0.000678	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CDKN1B—ovarian cancer	0.000356	0.0017	CbGpPWpGaD
Nelarabine—Nervous system disorder—Paclitaxel—ovarian cancer	0.000356	0.000676	CcSEcCtD
Nelarabine—Hypokalaemia—Doxorubicin—ovarian cancer	0.000355	0.000676	CcSEcCtD
Nelarabine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000355	0.000675	CcSEcCtD
Nelarabine—Adenosine triphosphate—ABCB1—ovarian cancer	0.000354	0.044	CrCbGaD
Nelarabine—ADA—Circadian rythm related genes—PTEN—ovarian cancer	0.000353	0.00168	CbGpPWpGaD
Nelarabine—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000352	0.000668	CcSEcCtD
Nelarabine—ADA—Metabolism—PPP1CC—ovarian cancer	0.00035	0.00166	CbGpPWpGaD
Nelarabine—ADA—Metabolism—BRIP1—ovarian cancer	0.00035	0.00166	CbGpPWpGaD
Nelarabine—Anaemia—Docetaxel—ovarian cancer	0.000348	0.000662	CcSEcCtD
Nelarabine—Anorexia—Paclitaxel—ovarian cancer	0.000346	0.000657	CcSEcCtD
Nelarabine—Muscular weakness—Doxorubicin—ovarian cancer	0.000344	0.000655	CcSEcCtD
Nelarabine—Vomiting—Vinorelbine—ovarian cancer	0.000343	0.000652	CcSEcCtD
Nelarabine—DGUOK—Metabolism—CAV1—ovarian cancer	0.000342	0.00163	CbGpPWpGaD
Nelarabine—Neutropenia—Epirubicin—ovarian cancer	0.000341	0.000648	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CCND1—ovarian cancer	0.00034	0.00162	CbGpPWpGaD
Nelarabine—Abdominal distension—Doxorubicin—ovarian cancer	0.00034	0.000646	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—MLH1—ovarian cancer	0.00034	0.00162	CbGpPWpGaD
Nelarabine—Hypotension—Paclitaxel—ovarian cancer	0.000339	0.000644	CcSEcCtD
Nelarabine—Headache—Vinorelbine—ovarian cancer	0.000338	0.000642	CcSEcCtD
Nelarabine—Leukopenia—Docetaxel—ovarian cancer	0.000337	0.000641	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—SKP2—ovarian cancer	0.000336	0.0016	CbGpPWpGaD
Nelarabine—Loss of consciousness—Docetaxel—ovarian cancer	0.000331	0.00063	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000331	0.000628	CcSEcCtD
Nelarabine—Hyperglycaemia—Epirubicin—ovarian cancer	0.000329	0.000625	CcSEcCtD
Nelarabine—Cough—Docetaxel—ovarian cancer	0.000329	0.000625	CcSEcCtD
Nelarabine—Insomnia—Paclitaxel—ovarian cancer	0.000328	0.000624	CcSEcCtD
Nelarabine—Pneumonia—Epirubicin—ovarian cancer	0.000327	0.000622	CcSEcCtD
Nelarabine—Convulsion—Docetaxel—ovarian cancer	0.000326	0.000621	CcSEcCtD
Nelarabine—Paraesthesia—Paclitaxel—ovarian cancer	0.000326	0.000619	CcSEcCtD
Nelarabine—Infestation NOS—Epirubicin—ovarian cancer	0.000325	0.000618	CcSEcCtD
Nelarabine—Infestation—Epirubicin—ovarian cancer	0.000325	0.000618	CcSEcCtD
Nelarabine—POLA1—G1/S Transition—MYC—ovarian cancer	0.000324	0.00154	CbGpPWpGaD
Nelarabine—Dyspnoea—Paclitaxel—ovarian cancer	0.000323	0.000615	CcSEcCtD
Nelarabine—DCK—Metabolism—PPP1CC—ovarian cancer	0.000323	0.00154	CbGpPWpGaD
Nelarabine—DCK—Metabolism—BRIP1—ovarian cancer	0.000323	0.00154	CbGpPWpGaD
Nelarabine—Somnolence—Paclitaxel—ovarian cancer	0.000323	0.000613	CcSEcCtD
Nelarabine—Arthralgia—Docetaxel—ovarian cancer	0.000321	0.00061	CcSEcCtD
Nelarabine—Myalgia—Docetaxel—ovarian cancer	0.000321	0.00061	CcSEcCtD
Nelarabine—Chest pain—Docetaxel—ovarian cancer	0.000321	0.00061	CcSEcCtD
Nelarabine—Nausea—Vinorelbine—ovarian cancer	0.00032	0.000609	CcSEcCtD
Nelarabine—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000319	0.000606	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	0.000318	0.00151	CbGpPWpGaD
Nelarabine—Stomatitis—Epirubicin—ovarian cancer	0.000317	0.000603	CcSEcCtD
Nelarabine—Neutropenia—Doxorubicin—ovarian cancer	0.000316	0.0006	CcSEcCtD
Nelarabine—Decreased appetite—Paclitaxel—ovarian cancer	0.000315	0.0006	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000313	0.000595	CcSEcCtD
Nelarabine—Fatigue—Paclitaxel—ovarian cancer	0.000313	0.000595	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PIK3CG—ovarian cancer	0.000311	0.00148	CbGpPWpGaD
Nelarabine—Pain—Paclitaxel—ovarian cancer	0.00031	0.00059	CcSEcCtD
Nelarabine—Constipation—Paclitaxel—ovarian cancer	0.00031	0.00059	CcSEcCtD
Nelarabine—Confusional state—Docetaxel—ovarian cancer	0.00031	0.000589	CcSEcCtD
Nelarabine—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000308	0.000585	CcSEcCtD
Nelarabine—Oedema—Docetaxel—ovarian cancer	0.000308	0.000585	CcSEcCtD
Nelarabine—Epistaxis—Epirubicin—ovarian cancer	0.000307	0.000583	CcSEcCtD
Nelarabine—Infection—Docetaxel—ovarian cancer	0.000306	0.000581	CcSEcCtD
Nelarabine—Sinusitis—Epirubicin—ovarian cancer	0.000305	0.00058	CcSEcCtD
Nelarabine—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000304	0.000579	CcSEcCtD
Nelarabine—Pneumonia—Doxorubicin—ovarian cancer	0.000303	0.000575	CcSEcCtD
Nelarabine—Nervous system disorder—Docetaxel—ovarian cancer	0.000302	0.000573	CcSEcCtD
Nelarabine—Thrombocytopenia—Docetaxel—ovarian cancer	0.000301	0.000572	CcSEcCtD
Nelarabine—Infestation—Doxorubicin—ovarian cancer	0.000301	0.000572	CcSEcCtD
Nelarabine—Infestation NOS—Doxorubicin—ovarian cancer	0.000301	0.000572	CcSEcCtD
Nelarabine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000299	0.000568	CcSEcCtD
Nelarabine—POLA1—Mitotic M-M/G1 phases—BIRC5—ovarian cancer	0.000298	0.00142	CbGpPWpGaD
Nelarabine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000297	0.000564	CcSEcCtD
Nelarabine—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000295	0.000561	CcSEcCtD
Nelarabine—POLA1—S Phase—MYC—ovarian cancer	0.000294	0.0014	CbGpPWpGaD
Nelarabine—Stomatitis—Doxorubicin—ovarian cancer	0.000293	0.000558	CcSEcCtD
Nelarabine—Anorexia—Docetaxel—ovarian cancer	0.000293	0.000557	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	0.000292	0.00139	CbGpPWpGaD
Nelarabine—Hypoaesthesia—Epirubicin—ovarian cancer	0.00029	0.000552	CcSEcCtD
Nelarabine—Urinary tract disorder—Epirubicin—ovarian cancer	0.000288	0.000548	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—CCND2—ovarian cancer	0.000288	0.00137	CbGpPWpGaD
Nelarabine—Oedema peripheral—Epirubicin—ovarian cancer	0.000288	0.000547	CcSEcCtD
Nelarabine—Hypotension—Docetaxel—ovarian cancer	0.000287	0.000546	CcSEcCtD
Nelarabine—Connective tissue disorder—Epirubicin—ovarian cancer	0.000287	0.000545	CcSEcCtD
Nelarabine—Abdominal pain—Paclitaxel—ovarian cancer	0.000287	0.000545	CcSEcCtD
Nelarabine—Body temperature increased—Paclitaxel—ovarian cancer	0.000287	0.000545	CcSEcCtD
Nelarabine—Urethral disorder—Epirubicin—ovarian cancer	0.000286	0.000544	CcSEcCtD
Nelarabine—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000285	0.000541	CcSEcCtD
Nelarabine—Epistaxis—Doxorubicin—ovarian cancer	0.000284	0.00054	CcSEcCtD
Nelarabine—Sinusitis—Doxorubicin—ovarian cancer	0.000282	0.000537	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.00028	0.000533	CcSEcCtD
Nelarabine—Insomnia—Docetaxel—ovarian cancer	0.000278	0.000529	CcSEcCtD
Nelarabine—Paraesthesia—Docetaxel—ovarian cancer	0.000276	0.000525	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—CHEK2—ovarian cancer	0.000275	0.00131	CbGpPWpGaD
Nelarabine—Dyspnoea—Docetaxel—ovarian cancer	0.000274	0.000521	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PIK3CD—ovarian cancer	0.000274	0.0013	CbGpPWpGaD
Nelarabine—Somnolence—Docetaxel—ovarian cancer	0.000273	0.00052	CcSEcCtD
Nelarabine—Eye disorder—Epirubicin—ovarian cancer	0.000273	0.000519	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—MYC—ovarian cancer	0.000273	0.0013	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	0.000272	0.00129	CbGpPWpGaD
Nelarabine—Cardiac disorder—Epirubicin—ovarian cancer	0.000271	0.000515	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	0.00027	0.00129	CbGpPWpGaD
Nelarabine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000269	0.000511	CcSEcCtD
Nelarabine—Decreased appetite—Docetaxel—ovarian cancer	0.000267	0.000508	CcSEcCtD
Nelarabine—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000267	0.000507	CcSEcCtD
Nelarabine—Oedema peripheral—Doxorubicin—ovarian cancer	0.000266	0.000506	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000265	0.000505	CcSEcCtD
Nelarabine—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000265	0.000505	CcSEcCtD
Nelarabine—Fatigue—Docetaxel—ovarian cancer	0.000265	0.000504	CcSEcCtD
Nelarabine—Angiopathy—Epirubicin—ovarian cancer	0.000265	0.000504	CcSEcCtD
Nelarabine—Urethral disorder—Doxorubicin—ovarian cancer	0.000265	0.000503	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	0.000265	0.00126	CbGpPWpGaD
Nelarabine—Mediastinal disorder—Epirubicin—ovarian cancer	0.000263	0.0005	CcSEcCtD
Nelarabine—Constipation—Docetaxel—ovarian cancer	0.000263	0.0005	CcSEcCtD
Nelarabine—Pain—Docetaxel—ovarian cancer	0.000263	0.0005	CcSEcCtD
Nelarabine—Chills—Epirubicin—ovarian cancer	0.000262	0.000498	CcSEcCtD
Nelarabine—Asthenia—Paclitaxel—ovarian cancer	0.00026	0.000495	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	0.000258	0.00123	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CCND2—ovarian cancer	0.000257	0.00123	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—BRCA1—ovarian cancer	0.000257	0.00123	CbGpPWpGaD
Nelarabine—Mental disorder—Epirubicin—ovarian cancer	0.000256	0.000486	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	0.000255	0.00121	CbGpPWpGaD
Nelarabine—Malnutrition—Epirubicin—ovarian cancer	0.000254	0.000483	CcSEcCtD
Nelarabine—Feeling abnormal—Docetaxel—ovarian cancer	0.000253	0.000482	CcSEcCtD
Nelarabine—Eye disorder—Doxorubicin—ovarian cancer	0.000252	0.00048	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—CCNE1—ovarian cancer	0.000252	0.0012	CbGpPWpGaD
Nelarabine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000251	0.000478	CcSEcCtD
Nelarabine—Cardiac disorder—Doxorubicin—ovarian cancer	0.000251	0.000477	CcSEcCtD
Nelarabine—Dysgeusia—Epirubicin—ovarian cancer	0.000249	0.000473	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	0.000249	0.00118	CbGpPWpGaD
Nelarabine—Diarrhoea—Paclitaxel—ovarian cancer	0.000248	0.000472	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—TYMS—ovarian cancer	0.000248	0.00118	CbGpPWpGaD
Nelarabine—Back pain—Epirubicin—ovarian cancer	0.000246	0.000467	CcSEcCtD
Nelarabine—Angiopathy—Doxorubicin—ovarian cancer	0.000245	0.000466	CcSEcCtD
Nelarabine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000243	0.000463	CcSEcCtD
Nelarabine—Body temperature increased—Docetaxel—ovarian cancer	0.000243	0.000462	CcSEcCtD
Nelarabine—Abdominal pain—Docetaxel—ovarian cancer	0.000243	0.000462	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—PPP2R1A—ovarian cancer	0.000243	0.00116	CbGpPWpGaD
Nelarabine—Chills—Doxorubicin—ovarian cancer	0.000242	0.000461	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—TP53—ovarian cancer	0.000241	0.00115	CbGpPWpGaD
Nelarabine—Dizziness—Paclitaxel—ovarian cancer	0.00024	0.000456	CcSEcCtD
Nelarabine—Vision blurred—Epirubicin—ovarian cancer	0.00024	0.000455	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PIK3CB—ovarian cancer	0.000239	0.00114	CbGpPWpGaD
Nelarabine—Mental disorder—Doxorubicin—ovarian cancer	0.000237	0.00045	CcSEcCtD
Nelarabine—Malnutrition—Doxorubicin—ovarian cancer	0.000235	0.000447	CcSEcCtD
Nelarabine—Anaemia—Epirubicin—ovarian cancer	0.000235	0.000447	CcSEcCtD
Nelarabine—ADA—Metabolism—YAP1—ovarian cancer	0.000235	0.00112	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—BRCA2—ovarian cancer	0.000233	0.00111	CbGpPWpGaD
Nelarabine—Vomiting—Paclitaxel—ovarian cancer	0.000231	0.000438	CcSEcCtD
Nelarabine—Dysgeusia—Doxorubicin—ovarian cancer	0.00023	0.000438	CcSEcCtD
Nelarabine—Leukopenia—Epirubicin—ovarian cancer	0.000227	0.000432	CcSEcCtD
Nelarabine—Back pain—Doxorubicin—ovarian cancer	0.000227	0.000432	CcSEcCtD
Nelarabine—Headache—Paclitaxel—ovarian cancer	0.000227	0.000432	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—CCNE1—ovarian cancer	0.000225	0.00107	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	0.000225	0.00107	CbGpPWpGaD
Nelarabine—Loss of consciousness—Epirubicin—ovarian cancer	0.000223	0.000425	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—BIRC5—ovarian cancer	0.000223	0.00106	CbGpPWpGaD
Nelarabine—Cough—Epirubicin—ovarian cancer	0.000222	0.000422	CcSEcCtD
Nelarabine—Vision blurred—Doxorubicin—ovarian cancer	0.000222	0.000421	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—TYMS—ovarian cancer	0.000221	0.00105	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—IL6—ovarian cancer	0.000221	0.00105	CbGpPWpGaD
Nelarabine—Asthenia—Docetaxel—ovarian cancer	0.000221	0.000419	CcSEcCtD
Nelarabine—Convulsion—Epirubicin—ovarian cancer	0.00022	0.000419	CcSEcCtD
Nelarabine—Anaemia—Doxorubicin—ovarian cancer	0.000217	0.000413	CcSEcCtD
Nelarabine—DCK—Metabolism—YAP1—ovarian cancer	0.000216	0.00103	CbGpPWpGaD
Nelarabine—Arthralgia—Epirubicin—ovarian cancer	0.000216	0.000411	CcSEcCtD
Nelarabine—Chest pain—Epirubicin—ovarian cancer	0.000216	0.000411	CcSEcCtD
Nelarabine—Myalgia—Epirubicin—ovarian cancer	0.000216	0.000411	CcSEcCtD
Nelarabine—Nausea—Paclitaxel—ovarian cancer	0.000215	0.00041	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	0.000212	0.00101	CbGpPWpGaD
Nelarabine—Leukopenia—Doxorubicin—ovarian cancer	0.00021	0.0004	CcSEcCtD
Nelarabine—Diarrhoea—Docetaxel—ovarian cancer	0.00021	0.0004	CcSEcCtD
Nelarabine—Confusional state—Epirubicin—ovarian cancer	0.000209	0.000398	CcSEcCtD
Nelarabine—Oedema—Epirubicin—ovarian cancer	0.000207	0.000394	CcSEcCtD
Nelarabine—Loss of consciousness—Doxorubicin—ovarian cancer	0.000207	0.000393	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	0.000207	0.000983	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PTEN—ovarian cancer	0.000206	0.000981	CbGpPWpGaD
Nelarabine—Infection—Epirubicin—ovarian cancer	0.000206	0.000392	CcSEcCtD
Nelarabine—Cough—Doxorubicin—ovarian cancer	0.000205	0.00039	CcSEcCtD
Nelarabine—Convulsion—Doxorubicin—ovarian cancer	0.000204	0.000387	CcSEcCtD
Nelarabine—Nervous system disorder—Epirubicin—ovarian cancer	0.000203	0.000387	CcSEcCtD
Nelarabine—Dizziness—Docetaxel—ovarian cancer	0.000203	0.000387	CcSEcCtD
Nelarabine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000203	0.000386	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	0.000202	0.000962	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	0.000202	0.000962	CbGpPWpGaD
Nelarabine—Chest pain—Doxorubicin—ovarian cancer	0.0002	0.000381	CcSEcCtD
Nelarabine—Myalgia—Doxorubicin—ovarian cancer	0.0002	0.000381	CcSEcCtD
Nelarabine—Arthralgia—Doxorubicin—ovarian cancer	0.0002	0.000381	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—BIRC5—ovarian cancer	0.000199	0.000948	CbGpPWpGaD
Nelarabine—Anorexia—Epirubicin—ovarian cancer	0.000198	0.000376	CcSEcCtD
Nelarabine—Vomiting—Docetaxel—ovarian cancer	0.000196	0.000372	CcSEcCtD
Nelarabine—Hypotension—Epirubicin—ovarian cancer	0.000194	0.000368	CcSEcCtD
Nelarabine—Confusional state—Doxorubicin—ovarian cancer	0.000194	0.000368	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—TERT—ovarian cancer	0.000193	0.000918	CbGpPWpGaD
Nelarabine—Headache—Docetaxel—ovarian cancer	0.000193	0.000366	CcSEcCtD
Nelarabine—Oedema—Doxorubicin—ovarian cancer	0.000192	0.000365	CcSEcCtD
Nelarabine—ADA—Metabolism—FASN—ovarian cancer	0.000191	0.00091	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	0.000191	0.000909	CbGpPWpGaD
Nelarabine—Infection—Doxorubicin—ovarian cancer	0.000191	0.000362	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000189	0.000359	CcSEcCtD
Nelarabine—Nervous system disorder—Doxorubicin—ovarian cancer	0.000188	0.000358	CcSEcCtD
Nelarabine—ADA—Metabolism—SLC5A5—ovarian cancer	0.000188	0.000895	CbGpPWpGaD
Nelarabine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000188	0.000357	CcSEcCtD
Nelarabine—Insomnia—Epirubicin—ovarian cancer	0.000188	0.000357	CcSEcCtD
Nelarabine—Paraesthesia—Epirubicin—ovarian cancer	0.000186	0.000354	CcSEcCtD
Nelarabine—Dyspnoea—Epirubicin—ovarian cancer	0.000185	0.000352	CcSEcCtD
Nelarabine—Somnolence—Epirubicin—ovarian cancer	0.000184	0.000351	CcSEcCtD
Nelarabine—Anorexia—Doxorubicin—ovarian cancer	0.000183	0.000348	CcSEcCtD
Nelarabine—Nausea—Docetaxel—ovarian cancer	0.000183	0.000347	CcSEcCtD
Nelarabine—ADA—Metabolism—SLC2A1—ovarian cancer	0.000182	0.000865	CbGpPWpGaD
Nelarabine—Decreased appetite—Epirubicin—ovarian cancer	0.00018	0.000343	CcSEcCtD
Nelarabine—Hypotension—Doxorubicin—ovarian cancer	0.000179	0.000341	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000179	0.00034	CcSEcCtD
Nelarabine—Fatigue—Epirubicin—ovarian cancer	0.000179	0.00034	CcSEcCtD
Nelarabine—Pain—Epirubicin—ovarian cancer	0.000177	0.000337	CcSEcCtD
Nelarabine—Constipation—Epirubicin—ovarian cancer	0.000177	0.000337	CcSEcCtD
Nelarabine—DCK—Metabolism—FASN—ovarian cancer	0.000176	0.00084	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	0.000175	0.000835	CbGpPWpGaD
Nelarabine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000175	0.000332	CcSEcCtD
Nelarabine—ADA—Metabolism—CYP1B1—ovarian cancer	0.000174	0.000829	CbGpPWpGaD
Nelarabine—Insomnia—Doxorubicin—ovarian cancer	0.000174	0.00033	CcSEcCtD
Nelarabine—DCK—Metabolism—SLC5A5—ovarian cancer	0.000174	0.000826	CbGpPWpGaD
Nelarabine—Paraesthesia—Doxorubicin—ovarian cancer	0.000172	0.000328	CcSEcCtD
Nelarabine—Dyspnoea—Doxorubicin—ovarian cancer	0.000171	0.000325	CcSEcCtD
Nelarabine—Feeling abnormal—Epirubicin—ovarian cancer	0.000171	0.000325	CcSEcCtD
Nelarabine—Somnolence—Doxorubicin—ovarian cancer	0.000171	0.000324	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	0.00017	0.000808	CbGpPWpGaD
Nelarabine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.00017	0.000322	CcSEcCtD
Nelarabine—DCK—Metabolism—SLC2A1—ovarian cancer	0.000168	0.000798	CbGpPWpGaD
Nelarabine—Decreased appetite—Doxorubicin—ovarian cancer	0.000167	0.000317	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000166	0.000315	CcSEcCtD
Nelarabine—Fatigue—Doxorubicin—ovarian cancer	0.000165	0.000315	CcSEcCtD
Nelarabine—Constipation—Doxorubicin—ovarian cancer	0.000164	0.000312	CcSEcCtD
Nelarabine—Pain—Doxorubicin—ovarian cancer	0.000164	0.000312	CcSEcCtD
Nelarabine—Abdominal pain—Epirubicin—ovarian cancer	0.000164	0.000312	CcSEcCtD
Nelarabine—Body temperature increased—Epirubicin—ovarian cancer	0.000164	0.000312	CcSEcCtD
Nelarabine—DCK—Metabolism—CYP1B1—ovarian cancer	0.000161	0.000765	CbGpPWpGaD
Nelarabine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000158	0.000301	CcSEcCtD
Nelarabine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000157	0.000298	CcSEcCtD
Nelarabine—ADA—Metabolism—PPP2R1A—ovarian cancer	0.000154	0.000735	CbGpPWpGaD
Nelarabine—Abdominal pain—Doxorubicin—ovarian cancer	0.000152	0.000288	CcSEcCtD
Nelarabine—Body temperature increased—Doxorubicin—ovarian cancer	0.000152	0.000288	CcSEcCtD
Nelarabine—Asthenia—Epirubicin—ovarian cancer	0.000149	0.000283	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PIK3CA—ovarian cancer	0.000145	0.000692	CbGpPWpGaD
Nelarabine—ADA—Metabolism—ABCB1—ovarian cancer	0.000143	0.000683	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	0.000143	0.000682	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PPP2R1A—ovarian cancer	0.000143	0.000678	CbGpPWpGaD
Nelarabine—Diarrhoea—Epirubicin—ovarian cancer	0.000142	0.00027	CcSEcCtD
Nelarabine—ADA—Metabolism—TYMS—ovarian cancer	0.000141	0.00067	CbGpPWpGaD
Nelarabine—Asthenia—Doxorubicin—ovarian cancer	0.000138	0.000262	CcSEcCtD
Nelarabine—POLA1—Mitotic M-M/G1 phases—MAPK3—ovarian cancer	0.000138	0.000654	CbGpPWpGaD
Nelarabine—Dizziness—Epirubicin—ovarian cancer	0.000137	0.000261	CcSEcCtD
Nelarabine—DCK—Metabolism—ABCB1—ovarian cancer	0.000132	0.00063	CbGpPWpGaD
Nelarabine—Vomiting—Epirubicin—ovarian cancer	0.000132	0.000251	CcSEcCtD
Nelarabine—Diarrhoea—Doxorubicin—ovarian cancer	0.000131	0.00025	CcSEcCtD
Nelarabine—POLA1—Mitotic M-M/G1 phases—MAPK1—ovarian cancer	0.000131	0.000623	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	0.000131	0.000622	CbGpPWpGaD
Nelarabine—DCK—Metabolism—TYMS—ovarian cancer	0.00013	0.000619	CbGpPWpGaD
Nelarabine—Headache—Epirubicin—ovarian cancer	0.00013	0.000247	CcSEcCtD
Nelarabine—Dizziness—Doxorubicin—ovarian cancer	0.000127	0.000241	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—CCND1—ovarian cancer	0.000125	0.000593	CbGpPWpGaD
Nelarabine—Nausea—Epirubicin—ovarian cancer	0.000123	0.000234	CcSEcCtD
Nelarabine—Vomiting—Doxorubicin—ovarian cancer	0.000122	0.000232	CcSEcCtD
Nelarabine—Headache—Doxorubicin—ovarian cancer	0.00012	0.000229	CcSEcCtD
Nelarabine—DGUOK—Metabolism—AKT1—ovarian cancer	0.000119	0.000566	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CDKN1B—ovarian cancer	0.000117	0.000556	CbGpPWpGaD
Nelarabine—Nausea—Doxorubicin—ovarian cancer	0.000114	0.000217	CcSEcCtD
Nelarabine—ADA—Metabolism—CAV1—ovarian cancer	0.000113	0.00054	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CCND1—ovarian cancer	0.000112	0.000531	CbGpPWpGaD
Nelarabine—DCK—Metabolism—CAV1—ovarian cancer	0.000105	0.000498	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PIK3CG—ovarian cancer	0.000103	0.000492	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—MAPK3—ovarian cancer	0.000103	0.000489	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—MYC—ovarian cancer	0.0001	0.000476	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—MAPK1—ovarian cancer	9.79e-05	0.000466	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PIK3CG—ovarian cancer	9.54e-05	0.000454	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—MAPK3—ovarian cancer	9.2e-05	0.000438	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PIK3CD—ovarian cancer	9.09e-05	0.000433	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—MYC—ovarian cancer	8.94e-05	0.000426	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—MAPK1—ovarian cancer	8.75e-05	0.000416	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PIK3CD—ovarian cancer	8.39e-05	0.000399	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PIK3CB—ovarian cancer	7.92e-05	0.000377	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—TP53—ovarian cancer	7.34e-05	0.00035	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PIK3CB—ovarian cancer	7.31e-05	0.000348	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PTEN—ovarian cancer	6.85e-05	0.000326	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PTEN—ovarian cancer	6.32e-05	0.000301	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PIK3CA—ovarian cancer	4.83e-05	0.00023	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PIK3CA—ovarian cancer	4.46e-05	0.000212	CbGpPWpGaD
Nelarabine—ADA—Metabolism—AKT1—ovarian cancer	3.94e-05	0.000188	CbGpPWpGaD
Nelarabine—DCK—Metabolism—AKT1—ovarian cancer	3.64e-05	0.000173	CbGpPWpGaD
